Drug shortage
Cisatracurium Besylate Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · To Be Discontinued · updated May 6, 2026
Key facts
| Generic name | Cisatracurium Besylate Injection |
|---|---|
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) |
| Dosage form | Injection |
| Status | To Be Discontinued |
| Therapeutic category | Analgesia/Addiction |
| Package NDCs | 0409-1208-01 |
| First posted | May 6, 2026 |
| Last updated | May 6, 2026 |
| Discontinued | May 6, 2026 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: